Literature DB >> 15331744

Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo.

Melanie Fiedler1, Florian Rödicker, Valentina Salucci, Mengji Lu, Luigi Aurisicchio, Uta Dahmen, Li Jun, Olaf Dirsch, Brigitte M Pützer, Fabio Palombo, Michael Roggendorf.   

Abstract

Alpha interferon (IFN-alpha) and IFN-gamma are able to suppress hepadnavirus replication. The intrahepatic expression of high levels of IFN may enhance the antiviral activity. We investigated the effects of woodchuck-specific IFN-alpha (wIFN-alpha) and IFN-gamma(wIFN-gamma) on woodchuck hepatitis virus (WHV) replication in vivo by helper-dependent adenoviral (HD-Ad) vector-mediated gene transfer. The expression of biologically active IFNs was demonstrated in vitro after transduction of woodchuck cells with HD-Ad vectors encoding wIFN-alpha (HD-AdwIFN-alpha) or wIFN-gamma (HD-AdwIFN-gamma). The transduction efficacy of the HD-Ad vector in woodchuck liver in vivo was tested with a vector expressing green fluorescence protein (GFP). Immunohistochemical staining of liver samples on day 5 after injection showed expression of GFP in a high percentage of liver cells surrounding the central vein. The transduction of livers of WHV carriers in vivo with HD-AdwIFN-alpha or HD-AdwIFN-gamma induced levels of biologically active IFN, which could be measured in the sera of these animals. Expression of wIFN-alpha in the liver reduced intrahepatic WHV replication and WHV DNA in sera of about 1 log step in two of two woodchucks. Transduction with HD-AdwIFN-gamma, however, reduced WHV replicative intermediates only slightly in two of three animals, which was not accompanied with significant changes in the WHV DNA in sera. We demonstrated for the first time the successful HD-Ad vector-mediated transfer of genes for IFN-alpha and IFN-gamma in vivo and timely limited reduction of WHV replication by wIFN-alpha, but not by wIFN-gamma. Copyright 2004 American Society for Microbiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331744      PMCID: PMC515010          DOI: 10.1128/JVI.78.18.10111-10121.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and Is independent of MxA.

Authors:  Andreas Rang; Michael Bruns; Tilman Heise; Hans Will
Journal:  J Biol Chem       Date:  2002-01-07       Impact factor: 5.157

2.  CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.

Authors:  Robert Thimme; Stefan Wieland; Carola Steiger; John Ghrayeb; Keith A Reimann; Robert H Purcell; Francis V Chisari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector.

Authors:  I H Kim; A Józkowicz; P A Piedra; K Oka; L Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 4.  Treatment of chronic hepatitis B: case selection and duration of therapy.

Authors:  Nancy Leung
Journal:  J Gastroenterol Hepatol       Date:  2002-04       Impact factor: 4.029

5.  Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes.

Authors:  Mengji Lu; Beate Lohrengel; Gero Hilken; Thekla Kemper; Michael Roggendorf
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Expression of a new woodchuck IFN-alpha gene by a helper-dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes.

Authors:  Valentina Salucci; Mengji Lu; Luigi Aurisicchio; Nicola La Monica; Michael Roggendorf; Fabio Palombo
Journal:  J Interferon Cytokine Res       Date:  2002-10       Impact factor: 2.607

7.  Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice.

Authors:  P Merle; M Chevallier; R Levy; M Maisonnas; O Terradillos; C Trépo; M A Buendia; L Vitvitski-Trépo
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

8.  Replication of naturally occurring woodchuck hepatitis virus deletion mutants in primary hepatocyte cultures and after transmission to naive woodchucks.

Authors:  M Lu; G Hilken; D Yang; T Kemper; M Roggendorf
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction.

Authors:  F Rödicker; T Stiewe; S Zimmermann; B M Pützer
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

10.  Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.

Authors:  L G Guidotti; P Borrow; M V Hobbs; B Matzke; I Gresser; M B Oldstone; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more
  11 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Measurement of Antiviral Effect and Innate Immune Response During Treatment of Primary Woodchuck Hepatocytes.

Authors:  Marta G Murreddu; Manasa Suresh; Severin O Gudima; Stephan Menne
Journal:  Methods Mol Biol       Date:  2017

3.  Regulated and liver-specific tamarin alpha interferon gene delivery by a helper-dependent adenoviral vector.

Authors:  Luigi Aurisicchio; Amedeo De Tomassi; Nicola La Monica; Gennaro Ciliberto; Cinzia Traboni; Fabio Palombo
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Authors:  Mariana Puntel; Ghulam Muhammad A K M; Catherine Farrokhi; Nathan Vanderveen; Christopher Paran; Ashley Appelhans; Kurt M Kroeger; Alireza Salem; Liliana Lacayo; Robert N Pechnick; Kyle R Kelson; Sukhpreet Kaur; Sean Kennedy; Donna Palmer; Philip Ng; Chunyan Liu; Johnny Krasinkiewicz; Pedro R Lowenstein; Maria G Castro
Journal:  Toxicol Appl Pharmacol       Date:  2013-02-09       Impact factor: 4.219

5.  Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.

Authors:  Anna D Kosinska; Ejuan Zhang; Mengji Lu; Michael Roggendorf
Journal:  Hepat Res Treat       Date:  2010-09-07

6.  Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Simon P Fletcher; Daniel J Chin; Lore Gruenbaum; Hans Bitter; Erik Rasmussen; Palanikumar Ravindran; David C Swinney; Fabian Birzele; Roland Schmucki; Stefan H Lorenz; Erhard Kopetzki; Jade Carter; Miriam Triyatni; Linta M Thampi; Junming Yang; Dalal AlDeghaither; Marta G Murreddu; Marta G Murredu; Paul Cote; Stephan Menne
Journal:  PLoS Pathog       Date:  2015-09-09       Impact factor: 6.823

7.  Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Kyle E Korolowicz; Radhakrishnan P Iyer; Stefanie Czerwinski; Manasa Suresh; Junming Yang; Seetharamaiyer Padmanabhan; Anjaneyulu Sheri; Rajendra K Pandey; Jeffrey Skell; Judith K Marquis; Bhaskar V Kallakury; Robin D Tucker; Stephan Menne
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

8.  The anti-HBV effect mediated by a novel recombinant eukaryotic expression vector for IFN-α.

Authors:  Haotian Yu; Zhaohua Hou; Qiuju Han; Cai Zhang; Jian Zhang
Journal:  Virol J       Date:  2013-08-29       Impact factor: 4.099

9.  Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter.

Authors:  Mohube Betty Mowa; Carol Crowther; Abdullah Ely; Patrick Arbuthnot
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

Review 10.  Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?

Authors:  Kristie Bloom; Mohube Betty Maepa; Abdullah Ely; Patrick Arbuthnot
Journal:  Genes (Basel)       Date:  2018-04-12       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.